Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) is a clinical-stage pharmaceutical company developing investigational therapies for endocrine conditions and neurodegenerative diseases, including conditions with high unmet medical needs. Its pipeline includes avexitide, a GLP-1 receptor antagonist being studied for… From the company’s description.
In fiscal 2025, Amylyx Pharmaceuticals, Inc. reported a net loss of $144.74M. Operations used $123.34M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Amylyx Pharmaceuticals, Inc. does
In the company’s own words
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) is a clinical-stage pharmaceutical company developing investigational therapies for endocrine conditions and neurodegenerative diseases, including conditions with high unmet medical needs. Its pipeline includes avexitide, a GLP-1 receptor antagonist being studied for post-bariatric hypoglycemia (PBH); AMX0035, an oral combination of sodium phenylbutyrate and taurursodiol under investigation for Wolfram syndrome; AMX0114, an antisense oligonucleotide targeting calpain-2 in amyotrophic lateral sclerosis; and AMX0318, a long-acting GLP-1 receptor antagonist candidate for PBH and other rare diseases. Avexitide is in a Phase 3 PBH trial, AMX0035 has been evaluated in a Phase 2 Wolfram syndrome trial, and AMX0114 is in Phase 1 testing. Amylyx also engages in research collaborations and works with external institutions on clinical research. The company relies on contract manufacturers to produce its candidates for clinical development. It has no reportable business segments described here. Its website is www.amylyx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1658551
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Amylyx Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Amylyx Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Amylyx Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Amylyx Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Amylyx Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”